Tracheobronchomalacia (TBM) is a condition characterized by abnormal softness of the trachea and bronchi, leading to their narrowing and/or collapse, especially under conditions of increased respiratory flow. The disease can affect both children and adults and is associated with a disruption of the structure of the cartilage that supports the airways. Patients with tracheobronchomalacia may experience a range of symptoms, including chronic cough, difficulty breathing, and wheezing. TBM may be an isolated disease or may develop against the background of other respiratory diseases, as well as in the presence of various congenital or acquired predisposing factors.
History of the disease and interesting historical facts
Tracheobronchomalacia was first described in the medical literature in the mid-20th century. One of the first patients diagnosed and treated was a child with a congenital condition that presented with respiratory failure. Since then, TBM has been the subject of considerable research, linking it to various genetic and environmental factors. An important point in the history of tracheobronchomalacia treatment was the introduction of modern imaging techniques, which improved diagnosis and understanding of the disease mechanism. The patient population continues to grow as awareness of the disease improves and the number of people with chronic respiratory disease increases.
Epidemiology
Tracheobronchomalacia occurs with varying frequency in different population groups and may be dependent on age and genetic predisposition. In the general population, TBM is diagnosed in approximately 1-2% people, but in patients with chronic respiratory diseases, this figure may be as high as 10-15%. In children, congenital tracheobronchomalacia accounts for approximately 0.02–0.3% among newborns. These figures highlight the importance of early diagnosis and prompt treatment, as the disease can significantly reduce quality of life and lead to serious complications.
Genetic predisposition to this disease
Genetic predisposition to tracheobronchomalacia has been described in some familial cases. The most important genes associated with TBM are those responsible for the normal development of cartilage and connective tissues, such as collagen genes (COL1A1, COL2A1, and others). Mutations in these genes can lead to weakness of the cartilage structure, which contributes to the development of the disease. It has also been noted that some hereditary syndromes, such as Ehlers-Danlos syndrome and Marfan syndrome, may be associated with tracheobronchomalacia due to the disruption of the connective tissue structure.
Risk factors for the development of this disease
Risk factors for tracheobronchomalacia can be divided into physical and chemical. Physical risk factors include:
- Congenital anomalies of the respiratory tract.
- Previous respiratory tract infections leading to inflammation and swelling.
- Having other respiratory diseases, such as asthma or chronic bronchitis.
Chemical risk factors include:
- Long-term exposure to toxic chemicals and pollutants.
- Smoking and passive smoking.
- Allergens that cause chronic inflammatory processes in the respiratory tract.
It is also worth noting that adverse environmental conditions can serve as catalysts for the development of TBM.
Diagnosis of this disease
Diagnosis of tracheobronchomalacia involves the use of various methods that help identify symptoms and assess the degree of impairment. The main symptoms of TBM are:
- Chronic cough that does not respond to treatment.
- Difficulty breathing and wheezing.
- Frequent respiratory infections.
The following can be used for laboratory research:
- Spirometry to assess lung function.
- Allergy tests to identify possible allergens.
Radiological tests such as chest X-ray and CT scan can help visualize the airways. If necessary, bronchoscopy may be performed to evaluate the trachea and bronchi in more detail. Differential diagnosis should include other diseases that can also cause breathing difficulties, including asthma and COPD.
Treatment
Treatment of tracheobronchomalacia depends on the severity of the condition and may include basic approaches, pharmacological interventions, and surgical methods. Conservative treatment includes:
- Elimination of risk factors (lifestyle changes, smoking cessation).
- Pharmacotherapy - the use of bronchodilators and corticosteroids to reduce inflammation.
Surgical treatment may be required in cases of severe stenotic tracheobronchomalacia, where methods such as tracheoplasty or stent placement may be used.
List of medications used to treat this disease
The following drugs are used to treat tracheobronchomalacia:
- Salbutamol (bronchodilator, inhalation).
- Budesonide (a corticosteroid to reduce inflammation).
- Tiotropium (long-acting bronchodilator).
- Cetirizine (antihistamine for allergic reactions).
- Ambroxol (mucolytic to reduce mucus viscosity).
Disease monitoring
Management of tracheobronchomalacia involves regular medical examinations with assessment of clinical symptoms and lung function. Prognosis depends on early diagnosis and treatment, but without proper treatment the condition can progress and lead to complications such as respiratory infections, pulmonary hypertension and chronic respiratory failure.
Age-related features of the disease
The course of tracheobronchomalacia can vary significantly depending on the age group. In newborns and children, the disease is often associated with congenital anomalies and can manifest itself immediately after birth. In adults, TBM often develops against the background of chronic lung diseases and can manifest itself more covertly.
Questions and Answers
- What is tracheobronchomalacia? Tracheobronchomalacia is a condition in which the trachea and bronchi become soft and prone to collapse, leading to obstruction of the airway.
- What are the main symptoms of tracheobronchomalacia? The main symptoms include chronic cough, difficulty breathing, wheezing sounds during breathing, and frequent upper respiratory infections.
- How is tracheobronchomalacia diagnosed? Diagnosis includes clinical examination, laboratory and radiological tests such as spirometry, radiography and bronchoscopy.
- How is tracheobronchomalacia treated? Treatment can be conservative (drug therapy, treatment with bronchodilators) or surgical, depending on the severity of the condition.
- What risk factors contribute to the development of tracheobronchomalacia? Risk factors include congenital abnormalities, chronic respiratory disease, smoking, and exposure to toxic substances.
